Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Breast Cancer Research and Treatment|October 24, 2022
PIK3CA-mutations in breast cancerKristin Reinhardt, Kathrin Stückrath, Carolin Hartung, et al.
Journal of Medical Systems|July 4, 2026
AI-enabled clinical decision support in breast cancer care: a blinded multicenter benchmarking study comparing medically specialized with a general-purpose systemJonas Freudenberg, Johannes Knitza, Niklas Gremke, et al.
Geburtshilfe Und Frauenheilkunde|October 15, 2025
Correction: Vaccine Effectiveness in SARS-CoV-2-Infected Pregnant Women with Gestational Diabetes Mellitus: Results from a Multicenter Registry-Based Prospective Cohort Study in GermanyEike A Strathmann, Katharina S Weber, Babett Ramsauer, et al.
Geburtshilfe Und Frauenheilkunde|October 15, 2025
Vaccine Effectiveness in SARS-CoV-2-Infected Pregnant Women with Gestational Diabetes Mellitus: Results from a Multicenter Registry-Based Prospective Cohort Study in GermanyEike A Strathmann, Katharina S Weber, Babett Ramsauer, et al.
American Journal of Obstetrics and Gynecology|May 17, 2022
Gestational diabetes mellitus and COVID-19: results from the COVID-19-Related Obstetric and Neonatal Outcome Study (CRONOS)Helmut J Kleinwechter, Katharina S Weber, Nina Mingers, et al.
Geburtshilfe Und Frauenheilkunde|December 4, 2023
Multiple Gestation as a Risk Factor for SARS-CoV-2-Associated Adverse Maternal Outcome: Data From the COVID-19 Related Obstetric and Neonatal Outcome Study (CRONOS)Marina Sourouni, Ariane Germeyer, Manuel Feißt, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Geburtshilfe Und Frauenheilkunde|January 31, 2024
Correction: Multiple Gestation as a Risk Factor for SARS-CoV-2-Associated Adverse Maternal Outcome: Data From the COVID-19 Related Obstetric and Neonatal Outcome Study (CRONOS)Marina Sourouni, Ariane Germeyer, Manuel Feißt, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Pageof 1